Financhill
Sell
28

GLPGF Quote, Financials, Valuation and Earnings

Last price:
$31.29
Seasonality move :
6.45%
Day range:
$31.29 - $31.29
52-week range:
$22.39 - $33.45
Dividend yield:
0%
P/E ratio:
18.70x
P/S ratio:
6.51x
P/B ratio:
0.72x
Volume:
--
Avg. volume:
33
1-year change:
19.15%
Market cap:
$2.1B
Revenue:
$298.2M
EPS (TTM):
-$7.44

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GLPGF
Galapagos NV
$80.4M -- -0.12% -- --
CLYYF
Celyad Oncology SA
-- -- -- -- --
MDXH
MDxHealth SA
$28M -$0.26 23% -35.9% $7.0400
NYXH
Nyxoah SA
$2.3M -$0.65 198.31% -26.1% $11.23
UCBJY
UCB SA
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GLPGF
Galapagos NV
$31.29 -- $2.1B 18.70x $0.00 0% 6.51x
CLYYF
Celyad Oncology SA
$0.18 -- $7.5M -- $0.00 0% 37.01x
MDXH
MDxHealth SA
$3.3500 $7.0400 $165.8M -- $0.00 0% 1.60x
NYXH
Nyxoah SA
$4.87 $11.23 $209.5M -- $0.00 0% 28.90x
UCBJY
UCB SA
$140.78 -- $53.5B 37.83x $0.79 0.56% 7.35x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GLPGF
Galapagos NV
0.31% 0.871 0.4% 8.44x
CLYYF
Celyad Oncology SA
-- 0.910 -- --
MDXH
MDxHealth SA
110.38% 2.496 38.19% 0.98x
NYXH
Nyxoah SA
29.34% 3.060 14.4% 1.22x
UCBJY
UCB SA
21.7% 0.945 -- 1.00x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GLPGF
Galapagos NV
$70.5M -$56.2M -16.42% -16.48% -67.61% -$65.2M
CLYYF
Celyad Oncology SA
-- -- -- -- -- --
MDXH
MDxHealth SA
$16.6M -$3.5M -39.3% -548.42% -12.67% -$1M
NYXH
Nyxoah SA
-$288.6K -$28.5M -76.64% -96.48% -1238.32% -$25M
UCBJY
UCB SA
-- -- 10.75% 13.88% -- --

Galapagos NV vs. Competitors

  • Which has Higher Returns GLPGF or CLYYF?

    Celyad Oncology SA has a net margin of -286.67% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of -16.48% beat Celyad Oncology SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GLPGF
    Galapagos NV
    84.76% -$3.58 $2.9B
    CLYYF
    Celyad Oncology SA
    -- -- --
  • What do Analysts Say About GLPGF or CLYYF?

    Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Celyad Oncology SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than Celyad Oncology SA, analysts believe Galapagos NV is more attractive than Celyad Oncology SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLPGF
    Galapagos NV
    0 0 0
    CLYYF
    Celyad Oncology SA
    0 0 0
  • Is GLPGF or CLYYF More Risky?

    Galapagos NV has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison Celyad Oncology SA has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.796%.

  • Which is a Better Dividend Stock GLPGF or CLYYF?

    Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celyad Oncology SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Celyad Oncology SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLPGF or CLYYF?

    Galapagos NV quarterly revenues are $83.2M, which are larger than Celyad Oncology SA quarterly revenues of --. Galapagos NV's net income of -$238.4M is higher than Celyad Oncology SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 18.70x while Celyad Oncology SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.51x versus 37.01x for Celyad Oncology SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLPGF
    Galapagos NV
    6.51x 18.70x $83.2M -$238.4M
    CLYYF
    Celyad Oncology SA
    37.01x -- -- --
  • Which has Higher Returns GLPGF or MDXH?

    MDxHealth SA has a net margin of -286.67% compared to Galapagos NV's net margin of -29.2%. Galapagos NV's return on equity of -16.48% beat MDxHealth SA's return on equity of -548.42%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLPGF
    Galapagos NV
    84.76% -$3.58 $2.9B
    MDXH
    MDxHealth SA
    60.43% -$0.16 $79.6M
  • What do Analysts Say About GLPGF or MDXH?

    Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand MDxHealth SA has an analysts' consensus of $7.0400 which suggests that it could grow by 110.15%. Given that MDxHealth SA has higher upside potential than Galapagos NV, analysts believe MDxHealth SA is more attractive than Galapagos NV.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLPGF
    Galapagos NV
    0 0 0
    MDXH
    MDxHealth SA
    6 0 0
  • Is GLPGF or MDXH More Risky?

    Galapagos NV has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -557,066.812, suggesting its less volatile than the S&P 500 by 55706781.163%.

  • Which is a Better Dividend Stock GLPGF or MDXH?

    Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLPGF or MDXH?

    Galapagos NV quarterly revenues are $83.2M, which are larger than MDxHealth SA quarterly revenues of $27.4M. Galapagos NV's net income of -$238.4M is lower than MDxHealth SA's net income of -$8M. Notably, Galapagos NV's price-to-earnings ratio is 18.70x while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.51x versus 1.60x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLPGF
    Galapagos NV
    6.51x 18.70x $83.2M -$238.4M
    MDXH
    MDxHealth SA
    1.60x -- $27.4M -$8M
  • Which has Higher Returns GLPGF or NYXH?

    Nyxoah SA has a net margin of -286.67% compared to Galapagos NV's net margin of -1195.73%. Galapagos NV's return on equity of -16.48% beat Nyxoah SA's return on equity of -96.48%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLPGF
    Galapagos NV
    84.76% -$3.58 $2.9B
    NYXH
    Nyxoah SA
    -12.52% -$0.74 $84.7M
  • What do Analysts Say About GLPGF or NYXH?

    Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Nyxoah SA has an analysts' consensus of $11.23 which suggests that it could grow by 130.05%. Given that Nyxoah SA has higher upside potential than Galapagos NV, analysts believe Nyxoah SA is more attractive than Galapagos NV.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLPGF
    Galapagos NV
    0 0 0
    NYXH
    Nyxoah SA
    3 1 0
  • Is GLPGF or NYXH More Risky?

    Galapagos NV has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GLPGF or NYXH?

    Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLPGF or NYXH?

    Galapagos NV quarterly revenues are $83.2M, which are larger than Nyxoah SA quarterly revenues of $2.3M. Galapagos NV's net income of -$238.4M is lower than Nyxoah SA's net income of -$27.6M. Notably, Galapagos NV's price-to-earnings ratio is 18.70x while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.51x versus 28.90x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLPGF
    Galapagos NV
    6.51x 18.70x $83.2M -$238.4M
    NYXH
    Nyxoah SA
    28.90x -- $2.3M -$27.6M
  • Which has Higher Returns GLPGF or UCBJY?

    UCB SA has a net margin of -286.67% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of -16.48% beat UCB SA's return on equity of 13.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLPGF
    Galapagos NV
    84.76% -$3.58 $2.9B
    UCBJY
    UCB SA
    -- -- $14.5B
  • What do Analysts Say About GLPGF or UCBJY?

    Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than UCB SA, analysts believe Galapagos NV is more attractive than UCB SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLPGF
    Galapagos NV
    0 0 0
    UCBJY
    UCB SA
    0 0 0
  • Is GLPGF or UCBJY More Risky?

    Galapagos NV has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison UCB SA has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.475%.

  • Which is a Better Dividend Stock GLPGF or UCBJY?

    Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.56% to investors and pays a quarterly dividend of $0.79 per share. Galapagos NV pays -- of its earnings as a dividend. UCB SA pays out 15.96% of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GLPGF or UCBJY?

    Galapagos NV quarterly revenues are $83.2M, which are larger than UCB SA quarterly revenues of --. Galapagos NV's net income of -$238.4M is higher than UCB SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 18.70x while UCB SA's PE ratio is 37.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.51x versus 7.35x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLPGF
    Galapagos NV
    6.51x 18.70x $83.2M -$238.4M
    UCBJY
    UCB SA
    7.35x 37.83x -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is JetBlue The Best Airline Stock?
Is JetBlue The Best Airline Stock?

Following a general trend of improvement among airline stocks, shares…

Why Did Netflix Buy Warner Bros?
Why Did Netflix Buy Warner Bros?

Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…

Why Did SoFi Stock Drop?
Why Did SoFi Stock Drop?

Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…

Stock Ideas

Buy
64
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
56
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
59
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 40x

Alerts

Sell
50
PLAB alert for Dec 10

Photronics, Inc. [PLAB] is up 45.35% over the past day.

Buy
60
OLMA alert for Dec 10

Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.

Buy
84
TSAT alert for Dec 10

Telesat Corp. [TSAT] is up 3.07% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock